- Home
- » Tags
- » Thalidomide
Top View
- Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs
- BICALUTAMIDE -- Withdrawn Due to Accelerated Deaths
- Appendix B - Product Name Sorted by Applicant
- Thalidomide Metabolism by the CYP2C Subfamily1
- Thalidomide-Celgene-Epar-Product
- Antitumor Effects of Thalidomide Analogs in Human Prostate Cancer Xenografts Implanted in Immunodeficient Mice
- Invited Lecture Presented at the Canadian Society of Pharmacology and Therapeutics Annual Meeting
- The Hitchhiker's Guide to Clinical Pharmacology
- Pharmaceutical Compositions and Dosage Forms of Thalidomide
- FEP 5 Tier Rx Drug Formulary (607) Standard Option
- NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2014
- Thalidomide: the Tragedy of Birth Defects and the Effective Treatment of Disease
- Thalidomide Does Not Interact with P-Glycoprotein
- THALOMID U.S. Prescribing Information
- Early Refill Drug Utilization Review Drugs
- A Randomized Phase II Trial of Thalidomide, an Angiogenesis Inhibitor, in Patients with Androgen-Independent Prostate Cancer1
- 1. NAME of the MEDICINAL PRODUCT <Invented Name> 50 Mg
- Novel Chiral LC Methods for the Enantiomeric Separation of Bicalutamide and Thalidomide on Amylose Based Immobilized CSP
- Malignant Ascites As Only Manifestation of Metastatic Prostate Cancer
- Healthcare Professional Information Pack Refer to Package Insert* for Further Details (*Revlimid® / Pomalyst®)
- Drugs in Pregnancy Dana G
- Continuous Low Dose Thalidomide: a Phase II Study in Advanced Melanoma, Renal Cell, Ovarian and Breast Cancer
- Clinical Evidence of Pharmacokinetics Changes in Thalidomide Therapy
- THALOMID® (Thalidomide) Capsules 50 Mg, 100 Mg, & 200Mg
- Thalidomide, INN-Thalidomide
- [2016]. NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016
- No Role for Thalidomide in Leprosy
- For Health Professionals Who Care for Cancer Patients
- Metastatic Hormone-Relapsed Prostate Cancer [ID1359]
- Drug Regulation: History, Present and Future1 Lembit Rägo, Budiono Santoso
- Antiangiogenic Cocktail (Aac)
- Polymorphism of Spironolactone: an Unprecedented Case of Monotropy Turning to Enantiotropy with a Huge Difference in the Melting Temperatures Ivo B
- BORTEZOMIB, THALIDOMIDE and DEXAMETHASONE (VTD28) 28 Day Cycle
- Patterns of Pregnancy Exposure to Prescription FDA C, D and X Drugs in a Canadian Population
- VTD – Bortezomib, Thalidomide & Dexamethasone Multiple Myeloma
- First-Line Therapy with Either Bortezomib-Melphalan-Prednisone Or Lenalidomide-Dexamethasone Followed by Lenalidomide for Transp
- Repurposing of FDA Approved Drugs As COVID-19 Therapeutics: Safety Concerns and Contraindications Of
- Package Leaflet
- Drugs to Avoid Preconceptionally
- Prostate Cancer Chemotherapy in the Era of Targeted Therapy
- Ethical Challenges of Pregnancy Prevention Programs